Ultrasound AI Market Size to Surge to USD 22.03 Billion by 2035 at a CAGR of 26.62% – SNS Insider

The U.S. ultrasound AI market is projected to reach $9.27 billion by 2035, while the European market is forecast to reach $5.06 billion. Growth is expected to be driven by deep-learning adoption, expansion of point-of-care imaging, and shortages of trained sonographers, supporting demand for AI-enabled ultrasound workflows.

Analysis

This is not yet an investable revenue event: long-dated market-sizing studies typically embed aggressive penetration assumptions while omitting procurement friction, reimbursement uncertainty, and hospital IT integration costs. The near-term monetization bottleneck is less algorithm accuracy than workflow ownership—AI features must be embedded in installed ultrasound platforms, PACS/EHR systems, and service contracts before they create recurring software revenue. That favors GE HealthCare (GEHC), Philips (PHG), and Siemens Healthineers (SMMNY) over standalone imaging-AI vendors whose distribution costs and clinical-validation burden can overwhelm nominal TAM growth.

The more important 6-18 month effect is potential segmentation within equipment suppliers. AI-guided acquisition could expand point-of-care ultrasound usage among less-specialized clinicians, supporting premium probe replacement and software attach rates for GEHC and PHG; however, it may also commoditize basic image interpretation and pressure hardware ASPs if low-cost handheld systems gain acceptable diagnostic performance. Butterfly Network (BFLY) has the highest narrative sensitivity to this theme but also the greatest execution risk, given its need to prove durable utilization, reimbursement support, and improving gross-margin economics rather than simply adding AI features.

Consensus may overvalue the addressable-market headline while undervaluing procurement-cycle duration. Hospital capital budgets and clinical governance can delay broad deployments by 12-24 months, making this more likely to appear first as modest software-attach uplift than a discrete revenue inflection. The thesis is falsified positively if GEHC/PHG report accelerating digital or ultrasound organic growth with expanding segment margins; it is falsified negatively if AI investment rises without higher recurring revenue, or if handheld vendors continue to require heavy sales-and-marketing spend to sustain growth.

Key Decisions for Investors

• No immediate directional trade on the market forecast alone; treat it as a watch item until GEHC, PHG, or SMMNY quantify ultrasound AI bookings, recurring software attach, or backlog conversion in the next 1-3 earnings cycles.
• Prefer a 6-18 month quality pair: long GEHC / short BFLY in equal volatility weights. GEHC has installed-base distribution and service-channel leverage; BFLY carries greater dilution and commercialization risk. Reassess if BFLY demonstrates sustained utilization-led revenue acceleration and material gross-margin expansion for two consecutive quarters.
• For PHG, monitor whether imaging-margin recovery coincides with digital-health order growth before initiating exposure. A credible setup requires evidence that AI is improving mix rather than adding R&D expense; absent that, the ultrasound theme is insufficient to offset broader execution risk.
• Use BFLY as a high-beta sentiment alert rather than a core long: a sharp AI-driven rally without corresponding guidance, cash-burn improvement, or paid-subscription metrics would create a potential short opportunity over a 1-3 month horizon.